3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Hemangioma
3
Urinary Bladder Neoplasms
2
Sarcoma, Kaposi
2
Sarcoma
2
Multiple Myeloma
2
Melanoma
2
Hemangiosarcoma
2
Hemangioma, Cavernous, Central Nervous System
2
Breast Neoplasms
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
Ipilimumab
5
Radiotherapy
4
Nivolumab
4
Doxorubicin
4
CTLA-4 Antigen
4
pembrolizumab
3
Gemcitabine
3
cabozantinib
2
brostallicin
2
Sunitinib
2
Specimen Handling
2
Radiation Dose Hypofractionation
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Ifosfamide
2
Docetaxel
2
Biopsy
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tremelimumab
1
toripalimab
1
talimogene laherparepvec
1
spartalizumab
1
soblidotin
1
sintilimab
1
saracatinib
1
romidepsin
1
reolysin
1
perifosine
1
pazopanib
1
fludarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Histiocytoma, Malignant Fibrous
×
Propranolol
×
Clear all
NCT05961761
2023-07-27
PROPANE
Herlev and Gentofte Hospital
Phase 2
Recruiting
80 enrolled